PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-1302

just my thinking but then looking at the charts, with PharmAust quietly getting on with things and getting their ducks in a row and conserving cash puts it in pole position for seeing a spike in price when the market comes to the conclusion that the the science has more commercial value than 7.5c per share and 1c per option. Now, with an extremely tight registry and low cost operation and with major milestones ahead, there is a genuine opportunity to see a cracking rise in the time prior to the options expiring (about 300+ days away). Should that happen, the vast majority of those options sit with existing LT shareholders. Now, wouldn't that be nice.
Given Ken's research, I am thinking i need to sell when PAA take up a banner on HC, seems to signify the beginning of the end. You know, that desperate move to add a facade that you have something to crow about but the market knows you have already been over-hyped.

Oh geez, am I agreeing with Ken...
adreamer